---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-019900"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:12:45.945645+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# LIXTE Biotechnology regains Nasdaq equity compliance after $6.5M capital raise

## Summary
- Received Nasdaq hearings panel notice of compliance with Listing Rule 5550(b)(1) requiring min $2.5M equity.
- Compliance achieved after closing $5.0M placement (July 2) and $1.5M direct offering (July 8).
- Subject to Panel Monitor through July 15, 2026; further deficiency triggers immediate hearing requirement.
- CEO states regaining compliance underscores financial health as clinical trials progress in ovarian, colon, sarcoma.

## SEC filing metadata
- accession: 0001641172-25-019900
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000164117225019900/0001641172-25-019900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000164117225019900/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-019900
- JSON: https://secwatch.observer/filing/0001641172-25-019900.json
- Plain text: https://secwatch.observer/filing/0001641172-25-019900.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.